Neil Madison Cowen

This inventor holds 19 USPTO granted patents and 13 published patent applications, plus 4 CIPO patents and 6 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Essentialis, Inc., Dow Agrosciences LLC, Essentials, Inc.. Active years: 1999-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Neil Madison Cowen. Retrieved from https://idiyas.com/inventor/neil-madison-cowen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 13)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 6)

Average Co-Inventor Count = 1.4

ph-index = 9

Forward Citations = 236(Granted Patents)

Location History:

Zionsville, IN (US) (1999 - 2001)
Carlsbad, CA (US) (2007 - 2023)

Company Filing History:

5. 1 out of 834,570

Other

patents

Years Active: 1999-2025

Loading Chart...

Areas of Expertise:

Potassium ATP Channel Openers

Prader-Willi Syndrome

Smith-Magenis Syndrome

Pharmaceutical Formulations

Transgenic Plants

Acyl-ACP Thioesterase

Inbred Maize Line

Regulatory Sequences

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12419895 - Methods for treating subjects with Prader-Willi syndrome (2025-09-23),

2. 12343348 - Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome (2025-07-01),

3. 12178823 - Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome (2024-12-31),

4. 12109216 - Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome (2024-10-08),

5. 11786536 - Salts of potassium ATP channel openers and uses thereof (2023-10-17),

6. 11045478 - Salts of potassium ATP channel openers and uses thereof (2021-06-29),

7. 10874676 - Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome (2020-12-29),

8. 10456408 - Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome (2019-10-29),

9. 10085998 - Salts of potassium ATP channel openers and uses thereof (2018-10-02),

10. 10058557 - Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome (2018-08-28),

11. 9782416 - Pharmaceutical formulations of potassium ATP channel openers and uses thereof (2017-10-10),

12. 9765043 - Salts of potassium ATP channel openers and uses thereof (2017-09-19),

13. 9757384 - Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome (2017-09-12),

14. 9381202 - Salts of potassium ATP channel openers and uses thereof (2016-07-05),

15. 7799777 - Salts of potassium ATP channel openers and uses thereof (2010-09-21),

Title: Neil Madison Cowen: Innovator in Treating Genetic Disorders

Introduction

Neil Madison Cowen, based in Carlsbad, CA, is an accomplished innovator in the field of biotechnology, particularly noted for his contributions to treatment methodologies for genetic disorders. With a remarkable portfolio of 19 patents, Cowen has been at the forefront of developing novel pharmacological strategies aimed at improving the lives of individuals suffering from conditions such as Prader-Willi syndrome.

Latest Patents

Cowen's most recent patents focus on innovative methods for treating subjects with Prader-Willi syndrome and Smith-Magenis syndrome. His techniques involve the immediate or prolonged administration of specific potassium ATP (KATP) channel openers, often in conjunction with growth hormone. These methods are designed to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic, and compositional outcomes. Additionally, the patents detail pharmaceutical formulations, methods of administration, and dosing strategies that minimize adverse effects while enhancing therapeutic efficacy. This comprehensive approach also explores co-administration of KATP channel openers with other drugs to treat various disorders in both humans and animals.

Career Highlights

Throughout his career, Neil Cowen has contributed to pivotal advancements in pharmaceutical technologies. He has worked in renowned companies, including Essentialis, Inc. and Dow Agrosciences LLC, where he played a significant role in advancing therapeutic innovations.

Collaborations

Cowen has collaborated with esteemed professionals in his field, including Khaled A. Yamout and Katherine Armstrong. These partnerships have further bolstered his research and innovations, leading to significant developments in the treatment of various genetic disorders.

Conclusion

Neil Madison Cowen's work is a testament to the power of innovation in medicine. His substantial contribution of 19 patents reflects his commitment to improving treatment options for genetic conditions, ultimately striving to enhance patient outcomes and quality of life. As the field of biotechnology continues to evolve, Cowen’s pioneering efforts will undoubtedly leave a lasting impact.

Profile summary based on public USPTO records.